Eli Lilly and Company (NYSE:LLY) down -0.99% to close at the price of $123.08. The stock has a market capitalization of $127.08 Billion however its outstanding shares are 1.03 Billion. The company’s beta value stood at 0.32.
Eli Lilly and Company (NYSE:LLY) has an ABR of 1.83 which is the combined stock view of 12 analysts poll results. As per Zacks simplified descending rating scale the ABR rank is displayed in the range of 1 to 5 where 1 represents Strong Buy and 5 a Strong Sell. As the name implies that ABR will show you the Average of Brokerage Recommendations on a given stock. It helps you quickly get a picture of where Wall Street stands on a stock without reading huge research reports. The smaller number of ABR is the more favorable. The modest value of the stock is known as the current ABR of the stock.
However out of 12 analysts 3 suggest Eli Lilly and Company (NYSE:LLY) a Strong Buy, 5 suggested Buy, 8 Hold and 0 Sell, while 0 analysts recommend the stock a Strong Sell.
Analysts are expecting average earnings estimates of $1.37 for the current quarter based on the opinion of 7 analysts, relating to high earnings per share estimates of $1.49 and low estimates of $1.21, however Eli Lilly and Company (NYSE:LLY) reported $1.34 earnings per share for the same quarter last year.
For the current quarter Eli Lilly and Company (NYSE:LLY) has average revenue estimates of $5.83 Billion, a total number of 5 analysts provided estimations over revenues. However the low revenue estimates for the company are $5.66 Billion versus high revenue estimates of $5.92 Billion. A year ago the company’s sales were $5700000 while its sales growth yearly estimates for the current quarter are 2.3%.
Taking a broader look at the analyst consensus, brokerage firms have a price target of $122 on Eli Lilly and Company (NYSE:LLY). Brokerage firms on the street have price targets on the name ranging from $93 to $145 based on 15 opinions.
Eli Lilly and Company (NYSE:LLY) as of current trade, has shown weekly performance of -2.58% which was maintained at 3% in one month period. Year to date performance remained at 6.36%. During the past three months the stock gain 7.49%, however six months performance of the stock remained at 16.51%. Eli Lilly and Company (NYSE:LLY)’s price sits 2.54% above from its SMA 50 of $121.91 and 15.26% far from the SMA 200 which is at $113.82.
Currently Eli Lilly and Company (NYSE:LLY)’s shares owned by insiders are 11.4%, whereas shares owned by institutional owners are 81.8%. However the six-month change in the insider ownership was recorded -2.37%, as well as three-month change in the institutional ownership was recorded 0.05%.
The stock is trading -5.87% away from its 52 week high of $130.75 and 65.19% far from the stock’s low point over the past 52 weeks, which was $74.51.
The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. Eli Lilly and Company (NYSE:LLY)’s price to earnings ratio stood at 37.29. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. A low P/E can indicate either that a company may currently be undervalued or that the company is doing exceptionally well relative to its past trends.
The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E. Eli Lilly and Company (NYSE:LLY) has a current PEG of 3.8. Eli Lilly and Company (NYSE:LLY)’s price to sales ratio for trailing twelve month stands at 5.18, whereas its price to book ratio for the most recent quarters is at 12.66. However the company’s price to cash per share for most recent quarter stands at 7.83. Its price to free cash flow for trailing twelve months is 15.71.